Am J Transplant, Volume 18, Suppl 3 Archives - Page 166 of 211 - ATC Abstracts

2018 American Transplant Congress
DonorNet and Biases in Decision-Making: An Organ Offer Simulation Study
D. Stewart,¹ J. Lindemans,² J. Schold,³ H. McGehee,¹ J. Kessler,⁴ C. Sullivan,⁴ M. Turner,² K. Mekeel,⁵ C. Berg,² R. Stratta,⁶ R. Formica,⁷ L. Ratner,⁸ D. Klassen,¹ B. Shepard.¹
¹UNOS, Richmond; ²Duke, Durham; ³CCF, Cleveland; ⁴Wharton, Philadelphia; ⁵UCSD, San Diego; ⁶Wake Forest, Winston-Salem; ⁷Yale, New Haven; ⁸Columbia, NY.
Background: Behavioral science research has revealed that the way information is presented can impact decision-making. UNOS has developed a DonorNet-like simulation tool to send hypothetical…
2018 American Transplant Congress
Early Outcomes and Risk Factors after Five Years of a Nationwide Strategy for Kidney Transplantation with Controlled Circulatory Death Donor (cDCD)
J. Portoles,^1,2 M. Perez Saez,² D. Hernandez,² J. Juega,² F. Moreso,² N. Maruri,² P. Lopez,^1,2 E. Melilli,² D. Navarro,² E. de Souza,² J. Ruiz,² M. Mazuecos,² A. Gutierrez,² I. Perez-Flores,² D. Janeiro,^1,2 J. Pascual.²
¹Nephrology, H Puerta de Hierro, Madrid, Spain; ²Nephrology, Spanish Multicentre Sentra-GEODAS Group, Madrid, Spain.
Study: prospective multicentre, systematic inclusion of every kidney transplants-KTx from controlled donation after circulatory death (cDCD) at joined units. Local center surgical and immunosuppressive protocols.Background:…
2018 American Transplant Congress
Differences in Rejection and Clinical Outcomes in Obese versus Non-Obese Renal Transplant Recipients Receiving Basiliximab Induction Immunosuppression
J. Benken,¹ C. Kane,² A. Lichvar,¹ E. Benedetti.¹
¹University of Illinois at Chicago, Chicago, IL; ²University of Northwestern Memorial Hospital, Chicago, IL.
Introduction: Basilixiab is a fixed-dose IL-2 receptor antagonist that is used for non-lymphodepleting induction therapy. The impact of obesity on basiliximab pharmacokinetics and pharmacodynamics is…
2018 American Transplant Congress
Anti-Thymocyte Globulin vs. Alemtuzumab: A Comparison of Long-Term Outcomes among Renal Transplant Recipients
E. Loncharic, A. Dodson, K. Gutierrez.
Department of Pharmacy, The University of Alabama at Birmingham, Birmingham, AL.
Background: Two lymphocyte depleting agents are currently available for renal transplant induction: alemtuzumab (C1H) and rabbit anti-thymocyte globulin (rATG). Studies comparing long-term outcomes between C1H…
2018 American Transplant Congress
Long-Term Follow Up of Living Kidney Donors with CKD at 1 Year after Nephrectomy
J. Na,¹ J. Park,¹ M-.G. Yoon,¹ H. Lee,² Y. Yoon,³ K. Huh,⁴ M. Kim,⁴ S. Kim,⁴ Y. Kim,⁴ W. Han.¹
¹Department of Urology, Yonsei University College of Medicine, Urological Science Institute, Seoul, Korea; ²Department of Urology, National Health Insurance Service Ilsan Hospital, Goyang-si, Korea; ³Department of Urology, Hanyang University Medical Center, Seoul, Korea; ⁴Department of Surgery-Transplantation, Yonsei University College of Medicine, Seoul, Korea.
Introduction:Many kidney donors show poor recovery after donation and the long-term prognosis of those patients has not been well studied. In this study we explored…
2018 American Transplant Congress
Kidney Transplant Outcome in the Patients with Lupus Nephritis
Y. Kim,¹ H. Lee,¹ H. Chin,² Y. Kim,^3,4 S. Han.¹
¹Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea; ²Internal Medicine, Seoul National University Bundang Hopsital, Seong-Nam, Republic of Korea; ³Medical Science, Seoul National University College of Medicine, Seoul, Republic of Korea; ⁴Kidney Research Institute, Seoul National University, Seoul, Republic of Korea.
Background: Despite improvements in overall prognosis in lupus nephritis, 10%-30% of patients with proliferative renal involvement progress to end stage renal disease, and kidney transplantation…
2018 American Transplant Congress
Evaluating PROMIS-57 Domains to Screen for Anxiety and Depression Using Legacy Instruments among Kidney Transplant Recipients
A. Bansal,¹ O. Ekundayo,¹ E. Tang,¹ F. Khalafi,¹ H. Ford,¹ M. Li,³ M. Novak,² I. Mucsi.¹
¹Multi-Organ Transplant Program, University Health Network, Toronto, ON, Canada; ²Centre for Mental Health, University Health Network, Toronto, ON, Canada; ³Department of Supportive Care, Princess Margaret Hospital, Toronto, ON, Canada.
BACKGROUNDDepression and anxiety are frequent among kidney transplant recipients (KTRs). We evaluate the accuracy of the Patient Reported Outcomes Measurement System (PROMIS 57 item) depression…
2018 American Transplant Congress
Single-Dose Pharmacokinetics and Pharmacodynamics of Belatacept in Adolescent Kidney Transplant Recipients
A. Moudgil,¹ V. Dharnidharka,² D. Feig,³ B. Warshaw,⁴ V. Perera,⁵ B. Murthy,⁵ M. Roberts,⁵ M. Polinsky,⁵ R. Ettenger.⁶
¹Children's National Medical Center, Washington, DC; ²Washington University, St. Louis, MO; ³University of Alabama, Birmingham, AL; ⁴Emory University & Children's Healthcare of Atlanta, Atlanta, GA; ⁵Bristol-Myers Squibb, Lawrenceville, NJ; ⁶University of California, Los Angeles, CA.
Purpose: To assess the pharmacokinetics (PK) and pharmacodynamic (PD) effect of a single dose of belatacept (bela) administered to adolescent kidney transplant recipients (KTR).Methods: In…
2018 American Transplant Congress
Differences in Pediatric and Adult Lost to Follow-Up Events for Heart, Kidney, and Liver Recipients
A. Robinson,¹ G. Mazariegos,² S. Bartosh,³ W. Mahle.⁴
¹United Network for Organ Sharing, Richmond, VA; ²Children's Hospital of Pittsburgh, Pittsburgh, PA; ³University of Wisconsin Hospital and Clinics, Madison, WI; ⁴Children's Healthcare of Atlanta, Atlanta, GA.
Background: Long-term follow-up data are necessary for accurate survival estimation. While the majority of heart (HR), kidney (KI), and liver (LI) transplant recipients (TxR) are…
2018 American Transplant Congress
Long-Term Social Outcome after Pediatric Kidney Transplantation
Y. Hamasaki,¹ T. Matsuda,¹ M. Kubota,¹ J. Hashimoto,¹ Y. Takahashi,¹ M. Muramatsu,² T. Kawamura,³ K. Sakai,² S. Shishido.^1,2
¹Pediatric Nephrology, Toho University Faculty of Medicine, Tokyo, Japan; ²Nephrology, Toho University Faculty of Medicine, Tokyo, Japan; ³Nephrology, Sakura Medical Center, Toho University, Sakura, Japan.
BackgroundPatients' and graft survival rates after pediatric kidney transplantation (KTx) were recently improved because of progress in immunosuppressants, perioperative care, and operative procedures. Therefore the…